Listen on the go
  • Listen on the Go
    • CORRECT!
    Next question
    touchONCOLOGY touchONCOLOGY

    Ovarian Cancer

    Watch interviews and latest expert perspectives on clinical best practice for optimzing the management of advanced ovarian cancer with PARP inhibitors as first-line maintenance therapy.

    Curriculum Activities

    Ovarian Cancer, Gynaecological Cancers
    Watch Time: 57 mins
    touchCONGRESS
    PARP inhibitors as first-line maintenance therapy in ovarian cancer: How can data from ESGO 2022 guide clinical practice?
    Prof. Jonathan Ledermann, Dr David Tan, Dr Anna Tinker

    Watch this two-part activity exploring the latest data on the use of PARP inhibitors in first-line maintenance therapy in ovarian cancer. Filmed following the ESGO European Congress on Gynaecological Oncology 2022. Part 1: Watch gynaecological cancer expert Prof. Jonathan Ledermann review key data from ESGO 2022 Watch Now Part 2: Watch leading experts consider what these data may mean for global and regional practice Select An Interview

    Learning objectives
    Learning Objectives
    • Outline the latest clinical trial data for PARP inhibitors in the first-line maintenance setting for advanced ovarian cancer
    • Describe real-world data on the use of PARP inhibitors in the first-line maintenance setting for advanced ovarian cancer
    • Discuss how the clinical trial and real-world data may impact the use of PARP inhibitors in clinical practice
    Ovarian Cancer, Gynaecological Cancers
    Watch Time: 35 mins
    touchIN CONVERSATION
    Maximizing the potential of PARP inhibitors as first-line maintenance therapy in ovarian cancer: Improving patient identification and treatment selection
    Prof. Nicoletta Colombo, Dr Natalia R Gómez-Hidalgo

    Watch ovarian cancer experts discuss key considerations for optimizing patient outcomes with PARP inhibitors as first-line maintenance therapy.

    Learning objectives
    Learning Objectives
    • Discuss the rationale for using PARP inhibitors in the first-line maintenance treatment of advanced ovarian cancer
    • Identify patients who may benefit from a PARP inhibitor in the first-line maintenance setting
    • Describe the key factors that can inform selection of the most appropriate PARP inhibitor for each patient
    Ovarian Cancer, Gynaecological Cancers
    Watch Time: 60 mins
    touchCONGRESS
    PARP inhibitors as first-line maintenance therapy in ovarian cancer: Using data from SGO 2022 to inform clinical best practice
    Dr Antonio González Martín, Dr Sandro Pignata, Prof. Isabelle Ray-Coquard Translations available:

    Watch this two-part activity exploring recent developments in the use of PARP inhibitors as first-line maintenance therapy in ovarian cancer. Filmed following the SGO Hybrid Annual Meeting on Women’s Cancer 2022. Part 1: Watch gynaecological cancer expert Prof. Isabelle Ray-Coquard review key data from the SGO Virtual Annual Meeting 2021 Watch Now Part 2: Choose from leading experts who discuss what these data may mean for global and regional practice Select An Interview

    Learning objectives
    Learning Objectives
    • Describe efficacy data for PARP inhibitors in the first-line maintenance treatment of ovarian cancer
    • Recall the safety data for PARP inhibitors in the first-line maintenance treatment of ovarian cancer
    • Evaluate how the latest data may impact the use of PARP inhibitors as first-line maintenance therapy in clinical practice

    Other Curriculum Activities

    Learn more with a series of activities which are linked and developed as a curriculum

    Multiple Myeloma
    touchCURRICULUM
    Multiple Myeloma

    Learn more about the role of BCMA-targeting agents in the treatment of multiple myeloma.

    Including:

    touchPANEL DISCUSSION

    Integrating BCMA-targeting agents into the treatment pathway for relapsed/refractory multiple myeloma

    touchCONGRESS

    Advances in the role of BCMA-targeting agents in multiple myeloma: An update from the EHA Congress 2021

    touchEXPERT OPINIONS

    Managing adverse events associated with BCMA-targeting agents in multiple myeloma: The role of the multidisciplinary team

    Multiple Myeloma
    Curriculum Inclusions:
    • Describe the potential of BCMA-targeting agents to improve outcomes for patients with multiple myeloma
    • Discuss the use of BCMA-targeting agents for relapsed/refractory multiple myeloma in clinical practice
    • Summarize the key adverse events associated with BCMA-targeting agents and how they can be managed
    Lung Cancer
    touchCURRICULUM
    Non-small cell lung cancer

    Watch interviews and expert perspectives covering the latest findings for the management of non-small cell lung cancer.

    Including:

    touchCONGRESS

    Progress in the management of EGFR-mutant NSCLC in 2020: Where are we now?

    touchPANEL DISCUSSION

    The role of MDTs in optimizing NSCLC management: From early disease and beyond

    touchEXPERT OPINIONS

    Progress in EGFR-mutant NSCLC: Where are we going?

    touchTALKS

    A moving target: Assessing the role of EGFR-TKIs in early-stage NSCLC

    Lung Cancer
    Curriculum Inclusions:
    • Recall latest key data on treatment outcomes in patients with EGFR-mutant NSCLC
    • Describe the benefits and ideal working practices of a modern multidisciplinary team to provide optimal care for patients with NSCLC
    • Discuss the importance of adherence to lung cancer guidelines for EGFR-mutation testing in the light of the recent evidence
    IME
    CME activities are developed by touchIME for touchONCOLOGY.

    Our education resources are developed in collaboration with our well established peer-reviewed medical journals, our Editorial Board members and partnerships with major medical societies, with a clear commitment to high-quality independent education.

    In Partnership with...
    Useful Links:
    About us Society Partners Press Releases Contact Us Permissions Terms & Conditions Privacy Policy Cookie Preferences
    Connect With Us:

    Other websites from Touch Medical Media:

    touchONCOLOGY
    touchOPHTHALMOLOGY
    touchENDOCRINOLOGY
    touchNEUROLOGY
    touchCARDIO
    touchRESPIRATORY
    touchIMMUNOLOGY
    touchINFECTIOUS DISEASES
    touchHAEMATOLOGY
    touchDERMATOLOGY

    Copyright® 2025 Touch Medical Media. Touch Medical Media Group Holdings Limited, a private limited company registered in England and Wales at 3 Stockport Exchange | Stockport | Cheshire | SK1 3GG | UK with registered number 08197142.

    touchONCOLOGY is for informational purposes and intended for healthcare professionals only. Its content should not be considered medical advice, diagnosis or treatment recommendations.

    Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
    Close Popup